Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Et studie for at lære mere om ændringen i blodniveauet af transthyretin, når deltagere med transthyretin-amyloidose med kardiomyopati skifter fra tafamidis til acoramidis (ACO-SWITCH)

10. november 2026 opdateret af: Bayer

Et prospektivt, enarms, fase 4-studie til evaluering af forløbet af serumtransthyretin (TTR)-niveau med acoramidis hos voksne patienter med variant eller vildtype transthyretin amyloidose med kardiomyopati (ATTR-CM), der tidligere er behandlet med tafamidis

Transthyretin (TTR) is a protein made by the liver that helps transport thyroid hormone and vitamin A in the blood. In some people, this protein breaks down and forms harmful clumps called amyloid. TTR amyloid gets deposited in the heart wall and stops it from pumping blood properly, which may lead to heart failure. The breakage in TTR protein can be age-related (wild-type ATTR-CM), or genetic (variant ATTR-CM).

The study drug, acoramidis, works by attaching itself to the TTR protein, making TTR more stable and less likely to break down and form amyloid (clumps). This helps to slow down the progression of the disease, improve heart function, and increase the TTR levels in the blood. Acoramidis is an approved treatment for wild-type or variant ATTR-CM in Europe and the United States.

Tafamidis is another drug that stabilizes TTR and prevents it from breaking down.

In this study, acoramidis will be studied in participants with ATTR--CM who were previously treated with tafamidis. The main purpose of this study is to assess the change in blood TTR levels after participants are switched from tafamidis to acoramidis. This will be studied to understand if acoramidis causes an increase in blood TTR levels beyond the levels achieved with tafamidis.

For this, the researchers will measure the change in the levels of TTR protein in participants' blood after 6 months of the treatment with acoramidis, or earlier if a participant stops the treatment before reaching that six-month mark.

All participants will continue taking tafamidis during the screening period. In the treatment period of the study, participants will take acoramidis as two tablets twice daily by mouth, for up to 6 months.

At the start of this study, the study doctors will review each participant's medical history and check their overall health. The study doctors will perform electrocardiograms (ECG), and measure blood pressure and heart rate. Researchers will also take blood and urine samples from the participants to measure levels of TTr, NT-proBNP, hs-TnT, hs-CRP, RBP4, eGFR, creatinine, cystatin-C, UACR, and TSH at the start of the study, and at various time points thereafter (during the study) to assess heart, kidney and thyroid function.

There will be a total of 9 study check-ins. Participants will visit the study site twice: at screening and at the end of treatment period. A study nurse will visit the participant's home 6 times, at the start of treatment, Weeks 1, 2, 3 and 4, then again at 3 months. The final check-in will be done by phone.

The study doctors will monitor the health of the participants regularly for any medical problems during follow-up visits. Participants will know the treatment they will receive during the study. Each participant could be in the study for about 8 months.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

50

Fase

  • Fase 4

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • Brussels Capital
      • Brussels, Brussels Capital, Belgien, 1070
        • Ikke rekrutterer endnu
        • Hôpital Erasme/Erasmus Ziekenhuis
    • West Flanders
      • Bruges, West Flanders, Belgien, 8000
        • Rekruttering
        • AZ St-Jan Brugge-Oostende A.V.
      • Naples, Italien, 80131
        • Ikke rekrutterer endnu
        • Azienda Ospedaliera Dei Colli_Monaldi - Malattie Rare e Genetiche Cardiovascolari
    • Apulia
      • Lecce, Apulia, Italien, 73100
        • Ikke rekrutterer endnu
        • Ospedale Vito Fazzi Lecce_Cardiologia e UTIC
    • Emilia-Romagna
      • Bologna, Emilia-Romagna, Italien, 40138
        • Rekruttering
        • Azienda Ospedaliero-Universitaria Di Bologna IRCCS_Policlinico Sant'Orsola_Cardiologia
    • Lombardy
      • Bergamo, Lombardy, Italien, 24127
        • Rekruttering
        • Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII - Cardiologia 1
      • Milan, Lombardy, Italien, 20138
        • Rekruttering
        • Centro Cardiologico Monzino S.p.A. - Cardiologia Peri-Operatoria e Imaging Cardiovascolare
      • Pavia, Lombardy, Italien, 27100
        • Ikke rekrutterer endnu
        • Fondazione IRCCS Policlinico San Matteo-SC Medicina Generale 2 - Centro Amiloidosi Sistemiche e Malattie ad Alta Complessità
    • Tuscany
      • Florence, Tuscany, Italien, 50134
        • Rekruttering
        • Careggi University Hospital_cardio intensive care unit
      • Pisa, Tuscany, Italien, 56124
        • Rekruttering
        • Fondazione Toscana Gabriele Monasterio_Pisa - Cardiologia e Medicina Cardiovascolare
      • Siena, Tuscany, Italien, 53100
        • Rekruttering
        • Azienda Ospedaliera Universitaria Senese - cardiologia
    • Veneto
      • Padova, Veneto, Italien, 35128
        • Rekruttering
        • Azienda Ospedale-Università di Padova-UOC Cardiologia
      • Oslo, Norge, 0424
        • Ikke rekrutterer endnu
        • Oslo Universitetssykehus HF, Rikshospitalet
      • Berlin, Tyskland, 10365
        • Trukket tilbage
        • Sana Klinikum Lichtenberg - Klinik für Innere Medizin II, Schwerpunkt Kardiologie
      • Hamburg, Tyskland, 20246
        • Trukket tilbage
        • Universitätsklinikum Hamburg Eppendorf (UKE)-Universitären Herz- und Gefäßzentrum Hamburg, Klinik für Kardiologie
    • Baden-Wurttemberg
      • Ulm, Baden-Wurttemberg, Tyskland, 89081
        • Trukket tilbage
        • Universitaetsklinikum Ulm | Klinik fuer Innere Medizin II
    • Hesse
      • Darmstadt, Hesse, Tyskland, 64287
        • Ikke rekrutterer endnu
        • KVZ Kardiovaskulaeres Zentrum Darmstadt GmbH
    • Mecklenburg-Vorpommern
      • Greifswald, Mecklenburg-Vorpommern, Tyskland, 17475
        • Trukket tilbage
        • Universitaetsmedizin Greifswald KöR- Klinik und Poliklinik für Innere Medizin B
    • North Rhine-Westphalia
      • Bonn, North Rhine-Westphalia, Tyskland, 53127
        • Trukket tilbage
        • Universitätsklinikum Bonn - Herzzentrum des Universitätsklinikums Bonn
    • Lower Austria
      • Sankt Pölten, Lower Austria, Østrig, 1210
        • Trukket tilbage
        • Universitätsklinikum St. Pölten - Lilienfeld - Klinische Abteilung für Innere Medizin 3
    • State of Vienna
      • Vienna, State of Vienna, Østrig, 3500
        • Ikke rekrutterer endnu
        • Klinik Ottakring - 3. Medizinische Abteilung mit Kardiologie, internistischer Intensivmedizin und Ambulanz
      • Vienna, State of Vienna, Østrig, 1090
        • Rekruttering
        • Medizinische Universität Wien- Universitätsklinik für Innere Medizin II, Klinische Abteilung für Kardiologie
      • Vienna, State of Vienna, Østrig, 1100
        • Rekruttering
        • Klinik Favoriten - 5.Medizinische Abteilung-Kardiologie
    • Styria
      • Vienna, Styria, Østrig, 1030
        • Rekruttering
        • Medizinische Universität Graz- Klinische Abteilung für Kardiologie
    • Upper Austria
      • Braunau am Inn, Upper Austria, Østrig, 5280
        • Rekruttering
        • Krankenhaus St. Josef Braunau | Innere Medizin I
    • Vorarlberg
      • Feldkirch, Vorarlberg, Østrig, 6800
        • Trukket tilbage
        • VIVIT - Landeskrankenhaus Feldkirch - Innere Medizin I, Kardiologie, Angiologie, Endokrinologie, Diabetologie, Intensivmedizin

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 90 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Participants must be 18 to 90 years of age inclusive, at the time of signing the informed consent.
  • Diagnosis of ATTR-CM; disease defining examination, i.e., Single Photon Emission Computed Tomography (SPECT) or SPECT/Computed Tomography (CT) or biopsy, within 24 months prior to Visit 1 (V1).
  • Participants must currently be treated with tafamidis and have used tafamidis for at least the previous 3 months prior to V1 and have adhered to tafamidis therapy.
  • New York Heart Association (NYHA) class ≤ II at V1.
  • Estimate glomerular filtration rate (eGFR) ≥ 30 mL/min/1.73m^2 at V1.
  • N-terminal pro-B-type Natriuretic Peptide (NT-proBNP) > 300 and ≤ 7000 pg/mL at V1.

Exclusion Criteria:

  • Prior liver or heart transplantation or planned within the next 12 months.
  • Current or planned use of ventricular assist device.
  • Active cancer or other disease that decreases the life expectancy to less than one year.
  • Heart failure due to ischemic heart disease.
  • Myocardial infarction, cardiovascular (CV) surgery, or unstable angina within the last 90 days prior to V1.
  • Confirmed diagnosis of light-chain amyloidosis.
  • Dialysis or severe renal impairment as reflected by Urinary Albumin Creatinine Ratio (UACR) > 300 mg/g at V1.
  • Major surgery within 90 days prior to V1.
  • Recent initiation of Sodium-Glucose-Cotransporter-2 inhibitors (SGLT2i) within 3 months before V1.
  • Initiation of treatment with a diuretic or increase in diuretic dose within 3 months before V1.
  • Treatment with calcium channel blockers (e.g., verapamil, diltiazem) or digitalis.
  • Recent CV hospitalization within 3 months before V1.
  • Known hypersensitivity to acoramidis or to any of the excipients.
  • A condition that, as judged by the investigator, would preclude compliance with the study protocol, such as a history of substance abuse, alcoholism, or a psychiatric condition.
  • Known or suspected liver disorder and bile secretion/flow (cholestasis, also history of it).
  • Abnormal liver function tests at V1, defined as ALT (GPT) or AST (GOT) ≥ 3 x ULN or total bilirubin ≥ 3 x ULN at V1.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Acoramidis

Participants will receive acoramidis 712 mg orally BID

356 mg film-coated tablets.

The recommended dose of acoramidis is 712 mg (two tablets, 356 mg) orally, twice daily, corresponding to a total daily dose of 1424 mg.

Andre navne:
  • BEYONTTRA
  • BAY3684938

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change in serum TTR level from baseline to month 6 or premature discontinuation of treatment
Tidsramme: From baseline to month 6 or premature discontinuation of treatment

TTR = Transthyretin

From baseline to month 6 or premature discontinuation of treatment

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Antal deltagere med TEAE'er og alvorlige TEAE'er
Tidsramme: Fra den første administration af undersøgelsesmedicinen til 30 dage efter den sidste dosis af undersøgelsesmedicinen eller studiet afsluttes, alt efter hvad der sker først
Fra den første administration af undersøgelsesmedicinen til 30 dage efter den sidste dosis af undersøgelsesmedicinen eller studiet afsluttes, alt efter hvad der sker først
Ændring fra baseline til måned 6 i kreatinin
Tidsramme: Fra baseline til måned 6
Fra baseline til måned 6
Ændring fra baseline til måned 6 i Cystatin C
Tidsramme: Fra baseline til måned 6
Fra baseline til måned 6
Change in serum TTR level from baseline to week 1, 2, 3, 4 and at month 3.
Tidsramme: At baseline, week 1, 2, 3, 4 and at month 3

TTR = Transthyretin

At baseline, week 1, 2, 3, 4 and at month 3
Change from baseline to month 6 of NT-proBNP
Tidsramme: From baseline to month 6

NT-proBNP = N-terminal pro-B-type Natriuretic Peptide

From baseline to month 6
Change from baseline to month 6 of hs-TnT
Tidsramme: From baseline to month 6

hs-TNT = high-sensitivity Troponin T

From baseline to month 6
Change from baseline to month 6 of RBP4
Tidsramme: From baseline to month 6

RBP4 = Retinol Binding Protein 4

From baseline to month 6
Signs of cardiac remodeling from baseline to month 6
Tidsramme: From baseline to month 6

These signs will be measured by echocardiogram

From baseline to month 6
Change from baseline to month 6 in 6MWD
Tidsramme: From baseline to month 6

The 6-Minute Walk distance (6MWD) measures the total distance that a participant could walk in 6 minutes.

From baseline to month 6
Change from baseline to month 6 in the eGFR
Tidsramme: From baseline to month 6

eGFR = estimated glomerular filtration rate

From baseline to month 6
Change from baseline to month 6 in UACR
Tidsramme: From baseline to month 6

UACR = Urinary Albumin Creatinine Ratio

From baseline to month 6
Change from baseline to month 6 in TSH
Tidsramme: From baseline to month 6

TSH = Thyroid Stimulating Hormone

From baseline to month 6
Change from baseline to month 6 in KCCQ-OS score
Tidsramme: From baseline to month 6

The Kansas City Cardiomyopathy Questionnaire-Overall Summary (KCCQ-OS) is 23-item questionnaire developed to measure health status and health-related quality of life (QoL) in individuals with heart failure. Items include heart failure symptoms, impact on physical and social functions, and how heart failure impacts QoL.

From baseline to month 6
Change from baseline to month 6 of EQ-5D-5L index score
Tidsramme: From baseline to month 6

The EuroQol-5-Dimension-5-Level (EQ-5D-5L) includes two parts. In the first part, participants are asked to rate their current health state on 5 dimensions (mobility, self-care, usual activities, pain or discomfort, and anxiety or depression) with each dimension having five levels of function (1-no problem, 2-slight problem, 3-moderate problem, 4-severe problem, and 5-extreme problem). The second part is a self-rating of current health status on a Visual Analogue Scale (EQ VAS) with endpoints labeled "best imaginable health state" (score of 100) and "worst imaginable health state" (score of 0). The scores from the 5 dimensions are used to calculate the index score.

From baseline to month 6

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

13. februar 2026

Primær færdiggørelse (Anslået)

17. september 2027

Studieafslutning (Anslået)

17. september 2027

Datoer for studieregistrering

Først indsendt

11. december 2025

Først indsendt, der opfyldte QC-kriterier

11. december 2025

Først opslået (Faktiske)

22. december 2025

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

12. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

10. november 2026

Sidst verificeret

16. oktober 2026

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • 23026
  • 2025-521831-35-00 (Registry Identifier: CTIS (EU))
  • 2025 (U.S. NIH-bevilling/kontrakt)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

IPD-planbeskrivelse

Currently, there is no established plan for the sharing of Individual Patient Data (IPD) from this study. The availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA 'Principles for responsible clinical trial data sharing.' This pertains to the scope, timepoint, and process of data access.

As such, Bayer commits to considering requests from qualified researchers for patient- / study-level clinical trial data, and documents from clinical trials involving medicines and indications approved in the US and EU. However, this commitment does not reflect an active IPD sharing plan. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014.

Researchers can use www.vivli.org to request access to IPD and documents from clinical studies to conduct research. Information on Bayer's criteria for listing studies is provided in the member section of the portal.

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .